Modeling Cancer with Pluripotent Stem Cells

Trends in Cancer

Volumn 2, Issue 9, 2016, Pages 485-494

  Gingold, Julian ^a   Zhou, Ruoji ^b,c   Lemischka, Ihor R ^d   Lee, Dung Fang ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cancer disease modeling; differentiation; genome editing; pluripotent stem cells

Indexed keywords

CANCER MODEL; CELL CULTURE; CELL DIFFERENTIATION; FAMILIAL CANCER; GLIOBLASTOMA; HUMAN; MYELODYSPLASTIC SYNDROME; NOONAN SYNDROME; PLURIPOTENT STEM CELL; PONTINE GLIOMA; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; NEOPLASM; ORGANOID;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ORGANOIDS; PLURIPOTENT STEM CELLS;

EID: 84989822616     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.07.007     Document Type: Review

References (95)

1. 1 Thomson, J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998), 1145–1147.
2. 2 Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
3. 3 Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
4. 4 Yu, J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007), 1917–1920.
5. 5 González, F., et al. Methods for making induced pluripotent stem cells: reprogramming à la carte. Nat. Rev. Genet. 12 (2011), 231–242.
6. 6 Murry, C.E., Keller, G., Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132 (2008), 661–680.
7. 7 Lancaster, M.A., Knoblich, J.A., Organogenesis in a dish: modeling development and disease using organoid technologies. Science, 345, 2014, 1247125.
8. 8 Yin, X., et al. Engineering stem cell organoids. Cell Stem Cell 18 (2016), 25–38.
9. 9 Grskovic, M., et al. Induced pluripotent stem cells – opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 10 (2011), 915–929.
10. 10 Dimos, J.T., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321 (2008), 1218–1221.
11. 11 Park, I.H., et al. Disease-specific induced pluripotent stem cells. Cell 134 (2008), 877–886.
12. 12 Yagi, T., et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20 (2011), 4530–4539.
13. 13 Brennand, K.J., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473 (2011), 221–225.
14. 14 Carvajal-Vergara, X., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465 (2010), 808–812.
15. 15 Pasca, S.P., et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat. Med. 17 (2011), 1657–1662.
16. 16 Itzhaki, I., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471 (2011), 225–229.
17. 17 Moretti, A., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363 (2010), 1397–1409.
18. 18 Rashid, S.T., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120 (2010), 3127–3136.
19. 19 Liu, G.H., et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8 (2011), 688–694.
20. 20 Smith-Arica, J.R., et al. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning Stem Cells 5 (2003), 51–62.
21. 21 Ivanova, N., et al. Dissecting self-renewal in stem cells with RNA interference. Nature 442 (2006), 533–538.
22. 22 Lee, D.F., et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 11 (2012), 179–194.
23. 23 Yusa, K., et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478 (2011), 391–394.
24. 24 Zou, J., et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5 (2009), 97–110.
25. 25 Hockemeyer, D., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27 (2009), 851–857.
26. 26 Luo, Y., et al. Generation of GFP reporter human induced pluripotent stem cells using AAVS1 safe harbor transcription activator-like effector nuclease. Curr. Protoc. Stem Cell Biol., 29, 2014 5A.7.1–5A.18.
27. 27 Ding, Q., et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12 (2013), 238–251.
28. 28 Mali, P., et al. RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
29. 29 Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
30. 30 Lee, D.F., et al. Modeling familial cancer with induced pluripotent stem cells. Cell 161 (2015), 240–254.
31. 31 Mulero-Navarro, S., et al. Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia. Cell Rep. 13 (2015), 504–515.
32. 32 Kotini, A.G., et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat. Biotechnol. 33 (2015), 646–655.
33. 33 Funato, K., et al. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27 M histone mutation. Science 346 (2014), 1529–1533.
34. 34 Duan, S., et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun., 6, 2015, 10068.
35. 35 Li, F.P., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48 (1988), 5358–5362.
36. 36 Dugimont, T., et al. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene 16 (1998), 2395–2401.
37. 37 Roberts, A.E., et al. Noonan syndrome. Lancet 381 (2013), 333–342.
38. 38 Lindsley, R.C., Ebert, B.L., Molecular pathophysiology of myelodysplastic syndromes. Annu. Rev. Pathol. 8 (2013), 21–47.
39. 39 Wu, G., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44 (2012), 251–253.
40. 40 Schwartzentruber, J., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 (2012), 226–231.
41. 41 Furnari, F.B., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21 (2007), 2683–2710.
42. 42 Si-Tayeb, K., et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51 (2010), 297–305.
43. 43 Goldman, O., et al. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell Stem Cell 12 (2013), 748–760.
44. 44 Hannan, N.R., et al. Production of hepatocyte-like cells from human pluripotent stem cells. Nat. Protoc. 8 (2013), 430–437.
45. 45 Spence, J.R., et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470 (2011), 105–109.
46. 46 Antonica, F., et al. Generation of functional thyroid from embryonic stem cells. Nature 491 (2012), 66–71.
47. 47 Dye, B.R., et al. In vitro generation of human pluripotent stem cell derived lung organoids. Elife, 4, 2015, e05098.
48. 48 Huang, S.X., et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat. Biotechnol. 32 (2014), 84–91.
49. 49 Huang, S.X., et al. The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Nat. Protoc. 10 (2015), 413–425.
50. 50 Xia, Y., et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat. Cell. Biol. 15 (2013), 1507–1515.
51. 51 Takasato, M., et al. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat. Cell Biol. 16 (2014), 118–126.
52. 52 Osakada, F., et al. Stepwise differentiation of pluripotent stem cells into retinal cells. Nat. Protoc. 4 (2009), 811–824.
53. 53 Nakano, T., et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10 (2012), 771–785.
54. 54 Mellough, C.B., et al. Efficient stage-specific differentiation of human pluripotent stem cells toward retinal photoreceptor cells. Stem Cells 30 (2012), 673–686.
55. 55 Lamba, D.A., et al. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 12769–12774.
56. 56 Yang, R., et al. Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells. Nat. Commun., 5, 2014, 3071.
57. 57 Kidwai, F.K., et al. Differentiation of epidermal keratinocytes from human embryonic stem cells. Methods Mol. Biol. 1195 (2014), 13–22.
58. 58 Grigoriadis, A.E., et al. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 115 (2010), 2769–2776.
59. 59 Kennedy, M., et al. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 109 (2007), 2679–2687.
60. 60 Chambers, S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27 (2009), 275–280.
61. – differentiated human ESCs. Stem Cells 25 (2007), 425–436.
62. 62 Fang, D., et al. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 24 (2006), 1668–1677.
63. 63 Lancaster, M.A., et al. Cerebral organoids model human brain development and microcephaly. Nature 501 (2013), 373–379.
64. 64 McCracken, K.W., et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516 (2014), 400–404.
65. 65 Matano, M., et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21 (2015), 256–262.
66. 66 Takebe, T., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499 (2013), 481–484.
67. 67 Takebe, T., et al. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat. Protoc. 9 (2014), 396–409.
68. 68 Boj, S.F., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
69. 69 Xia, Y., et al. The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. Nat. Protoc. 9 (2014), 2693–2704.
70. 70 Freedman, B.S., et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat. Commun., 6, 2015, 8715.
71. 71 Morizane, R., et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33 (2015), 1193–1200.
72. 72 Takasato, M., et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526 (2015), 564–568.
73. 73 Eiraku, M., et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 472 (2011), 51–56.
74. 74 Völkner, M., et al. Retinal organoids from pluripotent stem cells efficiently recapitulate retinogenesis. Stem Cell Reports 6 (2016), 525–538.
75. 75 Kuwahara, A., et al. Generation of a ciliary margin-like stem cell niche from self-organizing human retinal tissue. Nat. Commun., 6, 2015, 6286.
76. 76 Rouhani, F.J., et al. Mutational history of a human cell lineage from somatic to induced pluripotent stem cells. PLoS Genet., 12, 2016, e1005932.
77. 77 Somers, A., et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28 (2010), 1728–1740.
78. 78 Fukawatase, Y., et al. Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. Sci. Rep., 4, 2014, 5421.
79. 79 Garçon, L., et al. Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood 122 (2013), 912–921.
80. 80 Ge, J., et al. Dysregulation of the transforming growth factor β pathway in induced pluripotent stem cells generated from patients with Diamond Blackfan anemia. PLoS ONE, 10, 2015, e0134878.
81. 81 Li, L.B., et al. Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11 (2012), 615–619.
82. 82 Agarwal, S., et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464 (2010), 292–296.
83. 83 Batista, L.F., et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474 (2011), 399–402.
84. 84 Itoh, M., et al. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 8797–8802.
85. 85 Tolar, J., et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 131 (2011), 848–856.
86. 86 Raya, A., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460 (2009), 53–59.
87. 87 Ye, Z., et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114 (2009), 5473–5480.
88. 88 Tulpule, A., et al. Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 12 (2013), 727–736.
89. 89 Cheung, H.H., et al. Telomerase protects werner syndrome lineage-specific stem cells from premature aging. Stem Cell Reports 2 (2014), 534–546.
90. 90 Shimamoto, A., et al. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS ONE, 9, 2014, e112900.
91. 91 Thatava, T., et al. Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation. Stem Cell Res. Ther., 2, 2011, 48.
92. 92 Komor, A.C., et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533 (2016), 420–424.
93. 93 Menon, T., et al. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell 16 (2015), 367–372.
94. 94 Xie, F., et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome. Res. 24 (2014), 1526–1533.
95. 95 Bellin, M., et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 32 (2013), 3161–3175.